Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27563768 | 0.87 | MAOB (0.52) | MAOBARPPARDPPARAPPARG | |
| SCHEMBL508697 | 0.82 | MAOB (0.70) | MAOBPPARDPPARAPPARGMRGPRX4 | |
| SCHEMBL5515224 | 0.82 | MAOB (0.70) | MAOBPPARDPPARAPPARGMRGPRX4 | |
| SCHEMBL8761070 | 0.79 | ALOX5 (0.58) | MAOBMAOA | |
| SCHEMBL5512060 | 0.79 | MAOB (0.63) | MAOBMAOAMRGPRX4 | |
| SCHEMBL9370437 | 0.77 | MAOB (0.50) | MAOBARMAOA | |
| SCHEMBL14548566 | 0.76 | MAOB (0.66) | MAOBPPARDPPARAPPARGMRGPRX4 | |
| SCHEMBL18002747 | 0.76 | MAOB (0.69) | MAOBPPARGMRGPRX4 | |
| SCHEMBL695145 | 0.76 | AR (0.52) | MAOBARMRGPRX4 | |
| SCHEMBL14108489 | 0.75 | MAOB (0.64) | MAOBPPARDPPARAPPARGMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539694-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6846832-B2 | 2,3-dihydro-isoindol-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014856-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | MAOB, MAOA, COMT | MAOB 1/4885AR 2431/4885PPARD 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.